Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering...

Descripción completa

Detalles Bibliográficos
Autores principales: Murano, Chihiro, Igarashi, Akira, Yamauchi, Keiko, Inoue, Sumito, Watanabe, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806250/
https://www.ncbi.nlm.nih.gov/pubmed/31645848
http://dx.doi.org/10.17179/excli2019-1786
_version_ 1783461586326781952
author Murano, Chihiro
Igarashi, Akira
Yamauchi, Keiko
Inoue, Sumito
Watanabe, Masafumi
author_facet Murano, Chihiro
Igarashi, Akira
Yamauchi, Keiko
Inoue, Sumito
Watanabe, Masafumi
author_sort Murano, Chihiro
collection PubMed
description A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of the lesions at the primary site was observed, and the patient's respiratory condition improved. Previous reports showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimertinib dose of 80 mg are limited. The present case demonstrated that osimertinib could be a possible treatment option for EGFR exon 20 insertion-positive lung adenocarcinoma.
format Online
Article
Text
id pubmed-6806250
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Leibniz Research Centre for Working Environment and Human Factors
record_format MEDLINE/PubMed
spelling pubmed-68062502019-10-23 Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma Murano, Chihiro Igarashi, Akira Yamauchi, Keiko Inoue, Sumito Watanabe, Masafumi EXCLI J Case Report A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of the lesions at the primary site was observed, and the patient's respiratory condition improved. Previous reports showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimertinib dose of 80 mg are limited. The present case demonstrated that osimertinib could be a possible treatment option for EGFR exon 20 insertion-positive lung adenocarcinoma. Leibniz Research Centre for Working Environment and Human Factors 2019-10-07 /pmc/articles/PMC6806250/ /pubmed/31645848 http://dx.doi.org/10.17179/excli2019-1786 Text en Copyright © 2019 Murano et al. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.
spellingShingle Case Report
Murano, Chihiro
Igarashi, Akira
Yamauchi, Keiko
Inoue, Sumito
Watanabe, Masafumi
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
title Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
title_full Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
title_fullStr Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
title_full_unstemmed Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
title_short Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
title_sort osimertinib as treatment for egfr exon 20 insertion-positive lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806250/
https://www.ncbi.nlm.nih.gov/pubmed/31645848
http://dx.doi.org/10.17179/excli2019-1786
work_keys_str_mv AT muranochihiro osimertinibastreatmentforegfrexon20insertionpositivelungadenocarcinoma
AT igarashiakira osimertinibastreatmentforegfrexon20insertionpositivelungadenocarcinoma
AT yamauchikeiko osimertinibastreatmentforegfrexon20insertionpositivelungadenocarcinoma
AT inouesumito osimertinibastreatmentforegfrexon20insertionpositivelungadenocarcinoma
AT watanabemasafumi osimertinibastreatmentforegfrexon20insertionpositivelungadenocarcinoma

Ejemplares similares